ESR1 and breast carcinoma: Most recently, a randomized Phase I trial (NCT02792465), which evaluated advanced solid tumors, including ER+/HER2− breast cancer, showed clinical benefit rates of 12% and 25% in the CFI-402,257 alone arm and combined with fulvestrant, respectively [96].